Technology
Health
Biotechnology

Wave Life Sciences

$25.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.22 (5.04%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell WVE and other stocks, options, ETFs, and crypto commission-free!

About

Wave Life Sciences Ltd. Ordinary Shares, also called Wave Life Sciences, is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. Read More It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Employees
250
Headquarters
Singapore, Central Singapore
Founded
2012
Market Cap
870.43M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
281.68K
High Today
$25.89
Low Today
$24.09
Open Price
$24.41
Volume
128.24K
52 Week High
$56.00
52 Week Low
$22.90

Collections

Technology
Health
Biotechnology
Therapy
2015 IPO
Asia (Non-China)
Asia

News

Yahoo FinanceMay 22

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in New York on Wednesday, June 5, 2019 at 2:00 p.m. ET. A live webcast of the presentation will be available on the investor relations page of the Wav...

77
Yahoo FinanceMay 10

Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update

CAMBRIDGE, Mass., May 10, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the first quarter ended March 31, 2019 and provided a business update. “Since the start of the year, we have made significant progress advancing suvodirsen, our lead clinical program for the treatment of Duchenne muscular dystrophy patients amenable to ex...

175
Yahoo FinanceMay 2

Is WAVE Life Sciences Ltd. (WVE) A Good Stock To Buy ?

Is WAVE Life Sciences Ltd. (NASDAQ:WVE) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. It's not surprising given that hedge funds have access to better information and more resources to find the winners in the stock market. WAVE Life Sc...

704

Earnings

-$1.36
-$1.07
-$0.78
-$0.49
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.13 per share
Actual
-$1.36 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.